Allogeneic stem cell transplant

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Hematopoietic Stem Cell Support in Vasculitis

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years